With an unprecedented number of new investigational agents and companies in immuno-oncology (IO), it has been difficult to track and understand the current IO agents in clinical development and the clinical trials testing these agents. The CRI Anna-Maria Kellen Clinical Accelerator team presents an unbiased, neutral, scientifically curated, and timely updated analysis based on information collected from numerous trusted and publicly available sources.

We hope to inform the cancer research community through academic publications as it strives for efficiencies and innovation while avoiding duplication.

Landscape of Immuno-Oncology Drug Development

A comparison of global IO pipelines in 2017 and 2020. 4,720 immuno-oncology agents in six main classes were identified in August 2020, an increase of 233% since 2017. More details can be found in the Nature Reviews Drug Discovery article.

Please note that all landscape dashboards are integrated with the CRI iAtlas for further exploration of the molecular targets. 

The most recent overview immuno-oncology landscape publication is "Immuno-oncology drug development forges on despite COVID-19. " in Nature Reviews Drug Discovery (September 2020). 

Read more IO landscape publications 

IO Landscapes

Download a PDF of the latest CRI landscape figures

Data Sources: Cancer Research Institute (CRI) analytics derive from public data sources, including trade news, company press releases, academic publications, FDA announcements, clinicaltrials.gov, and conference reports, and proprietary data sources including, but not limited to, GlobalData. The analytical algorithm and visualizations are developed by and therefore sole property of Cancer Research Institute.

Subscribe to our email newsletter to receive the latest updates on our landscape analyses.

Do you want more information on the Clinical Accelerator? Contact us

*Immunotherapy results may vary from patient to patient.